Tumor-Associated SLe^x-Le^x Antigen Production Service at CD BioGlyco

SLe^x-Le^x is an important biomolecule that plays an essential role in processes such as cancer metastasis and inflammation. However, the complexity and rarity of its chemical structure make its study challenging. To better address your research questions, CD BioGlyco utilizes our specialized Glyco™ Vaccine Development Platform to offer a full range of Tumor-Associated Glycolipid Antigen Production Services, including tumor-associated sLe^x-Le^x antigen production service. Simply tell us your project goals and we will complete all the following experiments.

• Chemical synthesis

We synthesize the target molecule, sLe^x-Le^x antigen, through a chemical process that involves connecting two sugar chain structures: sLe^x and Le^x. The process requires the design and optimization of a multi-step reaction pathway involving the synthesis of sLe^x and Le^x monomers, protecting group introduction and removal, and the linking of the two monomers to ultimately yield the target compound sLe^x-Le^x antigen.

• Enzyme-catalyzed synthesis

We accomplish the synthesis of sLe^x-Le^x antigens under relatively mild conditions by using enzymatic catalysts such as glycosyltransferases, glycosyltransferase mimics, or polysaccharide synthases, and controlling the reaction conditions and catalytic mechanism.

Fig.1 Technologies in tumor-associated SLe^x-Le^x antigen production. (CD BioGlyco)

SLe^x-Le^x antigens are commonly expressed on the surface of tumor cells and play an essential role in tumor invasion and metastasis. Therefore, we provide the follow-up sLe^x-Le^x antigen anti-tumor vaccine development services to advance your cancer-related research.

Applications

• Levels of sLe^x-Le^x antigen can be detected in blood or urine and can therefore be used for early detection and assessment of tumors.
• SLe^x-Le^x antigen is considered to be a potent tumor-specific antigen and synthesis or extraction of it from tumor cells can be used to design cancer vaccines.

Frequently Asked Question

• What is the structure of the sLe^x-Le^x antigen?

The sLe^x-Le^x antigen is a disaccharide antigen consisting of two monosaccharide residues, sLe^x and Le^x, through specific linkages. In particular, the sLe^x structure contains a NeuAcα2-3Galβ1-4(Fucα1-3)GlcNAc unit and a Galβ1-4(Fucα1-3)GlcNAc unit. The Le^x structure consists of a Galβ1-4(Fucα1-3)GlcNAc unit. SLe^x and Le^x are linked together through the β1-4 bond of Gal residue, which together form the sLe^x - Le^x antigen.

• How is the sLe^x-Le^x antigen expressed through cell surface glycan groups?

The synthesis of sLe^x-Le^x antigen is associated with glycosyltransferases that catalyze the addition and attachment of monosaccharide residues to form the specific sugar chain structure of sLe^x-Le^x antigen.

At CD BioGlyco, our experienced scientists take care of all tumor-associated sLe^x-Le^x antigen production services, allowing clients to fully rely on the resultant data without having to invest extra time in antigen production or expensive laboratory equipment. For further details, please don't hesitate to contact us.

Reference

1. Nicolaou, K.C.; et al. Total synthesis of sialyl dimeric Le^x. Journal of the American Chemical Society. 1992, 114(8): 3126-3128.